Learn the correct technique for reconstituting lyophilised research peptides using bacteriostatic water for accurate, contamination-free preparations.
Written by the Peptide Labs Research Team
Reconstitution means dissolving lyophilised (freeze-dried) peptide in a liquid diluent. The standard diluent for most research peptides is bacteriostatic water (BAC water), which contains 0.9% benzyl alcohol to prevent microbial growth. Add it slowly down the vial wall, swirl gently, then label the vial and store it at 2–8°C.
Prepare a clean bench first. Wipe the work surface, wash hands or wear gloves, and wipe the rubber stoppers of the peptide vial and the BAC water vial with an alcohol wipe. Let them air dry for 30 seconds.
Measure the chosen volume of BAC water (1–2mL is standard for most peptides) and run it down the glass wall of the peptide vial, away from the powder cake. Swirl the vial in a circular motion. Dissolving takes 1–2 minutes, and the solution should be clear and colourless.
Concentration is the peptide amount divided by the diluent volume.
| BAC water added | Peptide amount | Concentration |
|---|---|---|
| 1mL | 10mg | 10mg/mL |
| 2mL | 10mg | 5mg/mL |
| 1mL | 5mg | 5mg/mL |
The peptide calculator works out concentration for a specific vial. Label every vial with the compound name, concentration and date of reconstitution.
Store it at 2–8°C in a refrigerator and protect it from light. Most reconstituted peptides remain stable for up to 4 weeks when stored properly.
Converts vial strength and diluent volume into insulin-syringe units.
The reconstituted vial holds 200 units in total on a 100-unit-per-mL scale.
2 mL is more than the 0.5 mL syringe holds, so a single draw cannot take the full volume.
Arithmetic only, for laboratory measurement. It does not recommend a quantity, and nothing here is a protocol. Research use only.
Common mistakes to avoid:
All information is for educational purposes related to in-vitro laboratory research. It is not medical advice or guidance for human use.
VRX-0075 is a preclinical quintuple agonist reported to reduce body weight more than retatrutide in rats. What the ADA 2026 abstract shows and does not.
ResearchBrenipatide (LY3537031) is Lilly's investigational GIP/GLP-1 agonist, in phase 3 for alcohol use disorder and depression. Registered trials and unknowns.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides